leading glp-1 medications 2025 Agonists Weight Loss Drugs Market Report, 2025-2030 The FDA recently approved the

Advanced glycation end products (AGEs) and diabetic vascular complications

[2] In people with type 2 diabetes, this two-part conversation becomes less effective a key reason blood sugar becomes harder to control

possible mechanism by suppressing 5-HT(2A) receptor-mediated activation of HPA axis

Consumers seeking weight management and energy enhancement have driven demand for fortified food-grade ingredients

The selectivity of FOXO4-DRI for senescent over non-senescent cells is mechanistically grounded: FOXO4 is expressed at low levels in most non-senescent adult cells, but is strongly upregulated in senescent cells

Head-to-Head: Jardiance (SGLT2i) vs